Product
Treatment B
Aliases
Treatment B (BDA MDI HFA)
9 clinical trials
9 indications
Indication
Healthy AdultsIndication
Healthy ParticipantsIndication
Healthy Adult ParticipantsIndication
Healthy SubjectsIndication
Allergic RhinitisIndication
Healthy Control ParticipantsIndication
Chronic Obstructive Pulmonary DiseaseIndication
AbuseIndication
MedicationClinical trial
A Phase 1, Open-label, Multiple-dose, One-sequence Crossover Study to Investigate the Effect of Repeated Oral Doses of a Strong CYP2C8 Inhibitor on the Steady-state Pharmacokinetics of Adagrasib in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2023-07-25
Clinical trial
A Phase 1, Randomized, Double-blind, Single-dose, Partial Replicate, 3-period Cross-over Study to Assess the Total Systemic Exposure Bioequivalence of Budesonide and Albuterol Delivered by BDA MDI Hydrofluoroolefin (HFO) Compared With BDA MDI (Hydrofluoroalkene) HFA.Status: Recruiting, Estimated PCD: 2024-05-13
Clinical trial
A Phase 1, Open-Label, Single-Dose, Randomized, 2-Period, 2-Treatment-Sequence Crossover Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy SubjectsStatus: Completed, Estimated PCD: 2015-03-01
Clinical trial
A Phase 1 Study to Assess the Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and the Effect of Food on ALXN2050 Pharmacokinetics in Healthy Adult ParticipantsStatus: Completed, Estimated PCD: 2022-12-24
Clinical trial
Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (Dymista) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo in an Environmental Exposure Unit (EEU)Status: Completed, Estimated PCD: 2021-12-04
Clinical trial
A Single-center, Randomized, Open-label, Three-period Crossover Study to Investigate the Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation, and the Food Effect of Alpelisib Granule Formulation in Adult Healthy VolunteersStatus: Completed, Estimated PCD: 2022-11-09
Clinical trial
A Randomized, Single Blind, 3-Period, 3-Treatment, Single-dose, Crossover Study to Assess the Relative Bioavailability of BGF Propellant 1 and BGF Propellant 2 Compared With BGF MDI HFA in Healthy SubjectsStatus: Completed, Estimated PCD: 2021-05-17
Clinical trial
A Phase I, Randomized, Double-blind, Single-dose, Partial Replicate, 3-way Cross-over Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFAStatus: Completed, Estimated PCD: 2023-04-11
Clinical trial
A Double-Blind, Randomized, Crossover Study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid UsersStatus: Not yet recruiting, Estimated PCD: 2024-12-01